EICHORPublic-registry site landscape for NCT03993171, “31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.”, a Multiple Sclerosis study sponsored by Clene Nanomedicine. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03993171 (registry record) |
| Study title | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. |
| Official title | A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis. |
| Sponsor | Clene Nanomedicine |
| Condition(s) | Multiple Sclerosis |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | gold nanocrystals |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03993171.
Eichor generates a preliminary site-risk snapshot for NCT03993171 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
